Plain-English translation of NCT07652281 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called SHR-5421 in people who have multiple myeloma—a blood cancer that has become resistant to or stopped responding to previous treatments. Researchers want to learn how safe this medication is, how your body handles it, and whether it can help slow or stop the cancer from growing. This is an early-stage study (Phase 1), which means the medication has shown promise in the lab but hasn't been widely tested in patients yet.
Multiple myeloma is a serious blood cancer, and many patients eventually develop resistance to current treatments, leaving them with limited options. This trial exists to evaluate whether this new medication could offer hope to patients whose cancer has stopped responding to standard therapies.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive multiple doses of the experimental medication SHR-5421, likely as an injection or infusion, over the course of the study. You would need to visit the study clinic regularly for blood tests, physical exams, and scans to monitor how the treatment is working and check for side effects. The study will track how your body absorbs and processes the medication, measure any changes in your cancer, and carefully monitor your safety throughout the trial.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment target
~97 participants
Started
July 2026
Primary completion
April 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junli Wang
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.